Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas
Status:
Active, not recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
This is a single-institution, single-arm phase II trial of Durvalumab combined with Radiation
Therapy (RT) for metastatic pancreatic cancer patients who have progressed through first-line
chemotherapy.